Reversing anticoagulant effects of novel oral anticoagulants: role of | VHRM
Table 1 from Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant. | Semantic Scholar
Idarucizumab | Circulation
Top Questions on DOAC Reversal
Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library
Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants - British Journal of Anaesthesia
Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - The American Journal of Emergency Medicine
Dosing and Preparation | Praxbind® (idarucizumab)
Idarucizumab | Circulation
Praxbind (Idarucizumab for Injection): Uses, Dosage, Side Effects, Interactions, Warning
These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND® (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015
Core PI template
Evidence supporting idarucizumab for the reversal of dabigatran - ScienceDirect
Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study | SpringerLink
Evidence Supporting Idarucizumab for the Reversal of Dabigatran - The American Journal of Medicine
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
BUY idarucizumab (Praxbind) 50 mg/mL from GNH India at the best price available.
Update on Reversal Agents for Novel Oral Anticoagulants - American College of Cardiology
